Can-Fite BioPharma (NYSEAMERICAN:CANF) Stock Price Down 3.4%
Can-Fite BioPharma (NYSEAMERICAN:CANF) Stock Price Down 3.4%
Can-Fite BioPharma Ltd. (NYSEAMERICAN:CANF – Get Rating) shares dropped 3.4% during mid-day trading on Thursday . The company traded as low as $1.66 and last traded at $1.73. Approximately 24,926 shares changed hands during trading, a decline of 70% from the average daily volume of 82,503 shares. The stock had previously closed at $1.79.
Can-Fite BioPharma Ltd.（纽约证券交易所美国证券交易所代码：CANF — 获取评级）股价在周四午盘交易中下跌了3.4％。该公司的交易价格低至1.66美元，最后一次交易价格为1.73美元。交易期间约有24,926股易手，较平均每日交易量82,503股下降了70％。该股此前收于1.79美元。
Analyst Ratings Changes
分析师评级变化
Several research firms have recently weighed in on CANF. StockNews.com upgraded Can-Fite BioPharma from a "sell" rating to a "hold" rating in a report on Saturday, April 1st. Dawson James cut Can-Fite BioPharma from a "buy" rating to a "neutral" rating in a research note on Tuesday, January 3rd. Finally, HC Wainwright restated a "buy" rating and issued a $34.00 price target on shares of Can-Fite BioPharma in a research note on Monday, March 13th.
几家研究公司最近对CANF进行了权衡。StockNews.com在4月1日星期六的一份报告中将Can-Fite BioPharma的评级从 “卖出” 上调至 “持有” 评级。道森·詹姆斯在1月3日星期二的一份研究报告中将Can-Fite BioPharma的评级从 “买入” 下调至 “中性” 评级。最后，HC Wainwright在3月13日星期一的一份研究报告中重申了 “买入” 评级，并对Can-Fite BioPharma的股票发布了34.00美元的目标股价。
Can-Fite BioPharma Price Performance
Can-Fite BioPharma 的价格表现
The firm has a 50 day moving average of $2.70 and a two-hundred day moving average of $1.97.
该公司的50天移动平均线为2.70美元，200天移动平均线为1.97美元。
Institutional Investors Weigh In On Can-Fite BioPharma
机构投资者正在关注 Can-Fite BioPharma
A hedge fund recently bought a new stake in Can-Fite BioPharma stock. Virtu Financial LLC acquired a new stake in shares of Can-Fite BioPharma Ltd. (NYSEAMERICAN:CANF – Get Rating) during the second quarter, according to its most recent filing with the SEC. The fund acquired 56,322 shares of the biotechnology company's stock, valued at approximately $52,000. Virtu Financial LLC owned 0.21% of Can-Fite BioPharma as of its most recent filing with the SEC. Institutional investors and hedge funds own 1.82% of the company's stock.
一家对冲基金最近购买了Can-Fite BioPharma股票的新股份。根据向美国证券交易委员会提交的最新文件，Virtu Financial LLC在第二季度收购了Can-Fite BioPharma Ltd.（纽约证券交易所美国证券交易所代码：CANF — 获取评级）的新股份。该基金收购了这家生物技术公司的56,322股股票，价值约52,000美元。截至最近向美国证券交易委员会提交文件，Virtu Financial LLC拥有Can-Fite BioPharma0.21％的股份。机构投资者和对冲基金拥有该公司1.82％的股票。
Can-Fite BioPharma Company Profile
Can-Fite BioPharma 公司简介
(Get Rating)
（获取评分）
Can-Fite BioPharma Ltd. is a biopharmaceutical company, which engages in the development of drugs for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. Its product pipeline include Piclidenoson, Namodenoson, and CF602. The company was founded by Pnina Fishman and Ilan Cohn on September 11, 1994 and is headquartered in Petach-Tikva, Israel.
Can-Fite BioPharma Ltd.是一家生物制药公司，从事治疗癌症、肝脏和炎症性疾病以及勃起功能障碍的药物的开发。其产品线包括 Piclidenoson、Namodenoson 和 CF602。该公司由Pnina Fishman和Ilan Cohn于1994年9月11日创立，总部位于以色列的Petach-Tikva。
Featured Stories
精选故事
- Get a free copy of the StockNews.com research report on Can-Fite BioPharma (CANF)
- MarketBeat Week in Review – 4/17 – 4/21
- 2 Industrial Strength Dividend Stocks Melting Up
- Proctor & Gamble Is Going To Set A New High
- AutoNation's Plans are Keeping Analysts Around
- Netflix Increases Buybacks: Can It Complete A Reversal In 2023?
- 免费获取 StockNews.com 关于 Can-Fite BioPharma（CANF）的研究报告的副本
- MarketBeat 周回顾 — 4 月 17 日 — 4 月 21 日
- 2 只工业实力股息股票正在融化
- 宝洁将创下新高
- AutoNation的计划让分析师待在身边
- Netflix 增加回购：它能否在 2023 年完成逆转？
Receive News & Ratings for Can-Fite BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Can-Fite BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
接收 Can-Fite BioPharma Daily 的新闻和评级 -在下面输入您的电子邮件地址，通过Marketbeat.com的免费每日电子邮件时事通讯接收Can-Fite BioPharma及相关公司的最新新闻和分析师评级的简明每日摘要。